GSK plc (LON:GSK) Insider Buys £8,120.40 in Stock

GSK plc (LON:GSK) insider Wendy Becker bought 536 shares of the firm’s stock in a transaction on Thursday, March 20th. The shares were bought at an average price of GBX 1,515 ($19.64) per share, with a total value of £8,120.40 ($10,529.56).

GSK Stock Performance

Shares of LON:GSK traded down GBX 2 ($0.03) during mid-day trading on Friday, reaching GBX 1,509 ($19.57). 21,366,055 shares of the company traded hands, compared to its average volume of 19,358,066. The company’s 50 day moving average price is GBX 1,438.13 and its 200-day moving average price is GBX 1,440. The firm has a market cap of £61.23 billion, a PE ratio of 24.38, a PEG ratio of 1.24 and a beta of 0.31. GSK plc has a 52 week low of GBX 1,282.50 ($16.63) and a 52 week high of GBX 1,823.50 ($23.64). The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, equities analysts expect that GSK plc will post 175.980975 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GSK. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Tuesday, January 7th. Berenberg Bank lowered their price objective on shares of GSK from GBX 1,820 ($23.60) to GBX 1,600 ($20.75) and set a “buy” rating on the stock in a research note on Friday, November 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,805.83 ($23.42).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.